Board briefs: Neuren; Peptech; Cytopia
Thursday, 10 February, 2005
Executives with US experience and contacts in the international equities market remain as popular as ever amongst Australian biotechs, if this week's board appointments are anything to go by.
Peptech (ASX:PTD) has appointed former Merrill Lynch CEO Greg Bundy as a non-executive director. After a 20-year career at Merrill Lynch, Bundy is now chairman of Equity Capital Markets. Bundy said he felt his international equities experience would add value to the board.
Peptech also confirmed that its UK-based investee Domantis, in which it holds a 36 per cent stake, is planning to list on the Nasdaq.
Former Pfizer/Pharmacia executive Graeme Howie - recently returned from New York - has joined Australia's newest biotech, Neuren Pharmaceuticals (ASX:NEU) as a non-executive director. His most recent role was leading the team developing recombinant human growth hormone Genotropin and related compounds.
Don Hulme and Nicholas Mathiou have resigned as directors of Cytopia (ASX:CYT). Cytopia is looking to recruit replacement directors who can bring M&A capabilities and experience in the international bioech community to the company.
Novel antibiotic activates 'suicide' mechanism in superbug
Researchers have discovered a new class of antibiotic that selectively targets Neisseria...
Modifications in the placenta linked to psychiatric disorders
Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...
ADHD may be linked with an increased risk of dementia
An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...
